With respect to the seven measured chemokines, CXCL5 and CCL23 were substantially decreased in the group of breast cancer patients, while those of CX3CL1 (fractalkine) and CCL5, were significantly elevated. This evidence concerns the gene CX3CL1 and breast carcinoma.